Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Transcription factor
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Potential drug targets === {{See also|Therapeutic gene modulation}} Approximately 10% of currently prescribed drugs directly target the [[nuclear receptor]] class of transcription factors.<ref name="pmid17139284">{{Cite journal |vauthors=Overington JP, Al-Lazikani B, Hopkins AL |date=December 2006 |title=How many drug targets are there? |journal=Nature Reviews. Drug Discovery |volume=5 |issue=12 |pages=993β6 |doi=10.1038/nrd2199 |pmid=17139284 |s2cid=11979420}}</ref> Examples include [[tamoxifen]] and [[bicalutamide]] for the treatment of [[breast cancer|breast]] and [[prostate cancer]], respectively, and various types of [[Glucocorticoid#Anti-inflammatory|anti-inflammatory]] and [[anabolic steroid|anabolic]] [[steroid]]s.<ref>{{Cite journal |vauthors=Gronemeyer H, Gustafsson JA, Laudet V |date=November 2004 |title=Principles for modulation of the nuclear receptor superfamily |journal=Nature Reviews. Drug Discovery |volume=3 |issue=11 |pages=950β64 |doi=10.1038/nrd1551 |pmid=15520817 |s2cid=205475111}}</ref> In addition, transcription factors are often indirectly modulated by drugs through [[signaling cascade]]s. It might be possible to directly target other less-explored transcription factors such as [[NF-ΞΊB#As a drug target|NF-ΞΊB]] with drugs.<ref name="pmid8049612">{{Cite journal |vauthors=Bustin SA, McKay IA |date=June 1994 |title=Transcription factors: targets for new designer drugs |journal=British Journal of Biomedical Science |volume=51 |issue=2 |pages=147β57 |pmid=8049612}}</ref><ref name="pmid7549464">{{Cite journal |vauthors=Butt TR, Karathanasis SK |year=1995 |title=Transcription factors as drug targets: opportunities for therapeutic selectivity |journal=Gene Expression |volume=4 |issue=6 |pages=319β36 |pmc=6134363 |pmid=7549464}}</ref><ref name="pmid9755455">{{Cite journal |vauthors=Papavassiliou AG |date=August 1998 |title=Transcription-factor-modulating agents: precision and selectivity in drug design |journal=Molecular Medicine Today |volume=4 |issue=8 |pages=358β66 |doi=10.1016/S1357-4310(98)01303-3 |pmid=9755455}}</ref><ref name="pmid15790306">{{Cite journal |vauthors=Ghosh D, Papavassiliou AG |year=2005 |title=Transcription factor therapeutics: long-shot or lodestone |journal=Current Medicinal Chemistry |volume=12 |issue=6 |pages=691β701 |doi=10.2174/0929867053202197 |pmid=15790306}}</ref> Transcription factors outside the nuclear receptor family are thought to be more difficult to target with [[small molecule]] therapeutics since it is not clear that they are [[drug design#Rational drug discovery|"drugable"]] but progress has been made on Pax2<ref name="pmid28094913">{{Cite journal |vauthors=Grimley E, Liao C, Ranghini E, Nikolovska-Coleska Z, Dressler G |year=2017 |title=Inhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain |journal=ACS Chemical Biology |volume=12 |issue=3 |pages=724β734 |doi=10.1021/acschembio.6b00782 |pmc=5761330 |pmid=28094913}}</ref><ref name="pmid29685496">{{Cite journal |vauthors=Grimley E, Dressler GR |year=2018 |title=Are Pax proteins potential therapeutic targets in kidney disease and cancer? |journal=Kidney International |volume=94 |issue=2 |pages=259β267 |doi=10.1016/j.kint.2018.01.025 |pmc=6054895 |pmid=29685496}}</ref> and the [[notch signaling pathway|notch]] pathway.<ref name="pmid19907488">{{Cite journal |vauthors=Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE |date=November 2009 |title=Direct inhibition of the NOTCH transcription factor complex |journal=Nature |volume=462 |issue=7270 |pages=182β8 |bibcode=2009Natur.462..182M |doi=10.1038/nature08543 |pmc=2951323 |pmid=19907488}} * {{lay source |template=cite magazine |author=Katherine Bagley |date=11 November 2009 |title=New drug target for cancer |url=http://www.the-scientist.com/blog/display/56143/ |archive-url=https://web.archive.org/web/20091116103443/http://www.the-scientist.com/blog/display/56143/ |archive-date=16 November 2009 |magazine=The Scientist}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)